Nitric Oxide Lung Diffusing Capacity in Systemic Sclerosis

Launched by HOLGER DRESSEL · Aug 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how well two different devices can measure the lung’s ability to transfer nitric oxide in patients with systemic sclerosis, a condition that can affect the lungs. Researchers want to understand if there are differences in the results these devices provide, especially in people who already have lung problems. The trial is currently looking for participants aged 18 and older who have been diagnosed with systemic sclerosis and have evidence of lung disease shown through a specific type of imaging test.

To participate, individuals must have a confirmed diagnosis of systemic sclerosis and a certain level of lung disease, and they must be able to give written consent. However, those with recent serious lung issues or pregnant women are not eligible. Participants can expect to undergo tests with the devices being studied, helping researchers learn more about how to evaluate lung health in people with this condition. This trial is important as it could lead to better ways to monitor and manage lung function in patients with systemic sclerosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed diagnosis of systemic sclerosis by American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR1) criteria (≥ 9 points)
• • Interstitial lung disease proven with high-resolution computed tomography (HRCT)
• • Written informed consent
• • Age ≥ 18 years
• Exclusion Criteria:
• • Unstable clinical condition affecting lung function testing (i.e., major hemoptoe/-tysis or pneumothorax within the last 3 months, acute respiratory tract infection in the past two weeks), others according to the assessment of the treating physician
• • Pregnancy